These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 15468129)

  • 41. Cervical cancer screening, abnormal cytology management, and counseling practices in the United States.
    Irwin K; Montaño D; Kasprzyk D; Carlin L; Freeman C; Barnes R; Jain N; Christian J; Wolters C
    Obstet Gynecol; 2006 Aug; 108(2):397-409. PubMed ID: 16880312
    [TBL] [Abstract][Full Text] [Related]  

  • 42. High risk HPV testing in the triage of repeat ASC-US and LSIL.
    Veijalainen O; Tuomisaari S; Luukkaala T; Mäenpää J
    Acta Obstet Gynecol Scand; 2015 Sep; 94(9):931-6. PubMed ID: 26053676
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Onclarity Human Papillomavirus Trial: Design, methods, and baseline results.
    Stoler MH; Wright TC; Parvu V; Vaughan L; Yanson K; Eckert K; Karchmer T; Kodsi S; Cooper CK
    Gynecol Oncol; 2018 Jun; 149(3):498-505. PubMed ID: 29681462
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Provider management of equivocal cervical cancer screening results among underserved women, 2009-2011: follow-up of atypical squamous cells of undetermined significance.
    Watson M; Benard V; Lin L; Rockwell T; Royalty J
    Cancer Causes Control; 2015 May; 26(5):759-64. PubMed ID: 25794897
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Adjunctive human papillomavirus DNA testing is a useful option in some clinical settings for disease risk assessment and triage of females with ASC-H Papanicolaou test results.
    Bandyopadhyay S; Austin RM; Dabbs D; Zhao C
    Arch Pathol Lab Med; 2008 Dec; 132(12):1874-81. PubMed ID: 19061283
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial.
    Ronco G; Segnan N; Giorgi-Rossi P; Zappa M; Casadei GP; Carozzi F; Dalla Palma P; Del Mistro A; Folicaldi S; Gillio-Tos A; Nardo G; Naldoni C; Schincaglia P; Zorzi M; Confortini M; Cuzick J;
    J Natl Cancer Inst; 2006 Jun; 98(11):765-74. PubMed ID: 16757701
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Application of high-risk human papillomavirus testing in women with abnormal cytology].
    Ou H; Bian ML; Zhang XY; Chen QY; Li M; Chen Y; Liu J
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2007 Oct; 29(5):608-11. PubMed ID: 18051714
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Human papillomavirus triage of patients with atypical squamous cells of undetermined significance on cervical Papanicolaou smear.
    Kirby TO; Huh WK; Partridge EE
    Ann Acad Med Singap; 2003 Sep; 32(5):590-5; quiz 596. PubMed ID: 14626785
    [TBL] [Abstract][Full Text] [Related]  

  • 49. HPV testing as a triage for borderline or mild dyskaryosis on cervical cytology: results from the Sentinel Sites study.
    Kelly RS; Patnick J; Kitchener HC; Moss SM;
    Br J Cancer; 2011 Sep; 105(7):983-8. PubMed ID: 21897395
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Introduction of liquid-based cytology and human papillomavirus testing in cervical cancer screening in Luxembourg.
    Latsuzbaia A; Hebette G; Fischer M; Arbyn M; Weyers S; Vielh P; Schmitt F; Mossong J
    Diagn Cytopathol; 2017 May; 45(5):384-390. PubMed ID: 28247516
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CITRUS, cervical cancer screening trial by randomization of HPV testing intervention for upcoming screening: Design, methods and baseline data of 18,471 women.
    Morisada T; Teramoto K; Takano H; Sakamoto I; Nishio H; Iwata T; Hashi A; Katoh R; Okamoto A; Sasaki H; Nakatani E; Teramukai S; Aoki D
    Cancer Epidemiol; 2017 Oct; 50(Pt A):60-67. PubMed ID: 28818742
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunocytochemical expression of p16INK4A and Ki-67 in cytologically negative and equivocal pap smears positive for oncogenic human papillomavirus.
    Longatto Filho A; Utagawa ML; Shirata NK; Pereira SM; Namiyama GM; Kanamura CT; Santos Gda C; de Oliveira MA; Wakamatsu A; Nonogaki S; Roteli-Martins C; di Loreto C; Mattosinho de Castro Ferraz Mda G; Maeda MY; Alves VA; Syrjänen K
    Int J Gynecol Pathol; 2005 Apr; 24(2):118-24. PubMed ID: 15782067
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Follow-up outcomes in a large cohort of patients with human papillomavirus-negative ASC-H cervical screening test results.
    Cohen D; Austin RM; Gilbert C; Freij R; Zhao C
    Am J Clin Pathol; 2012 Oct; 138(4):517-23. PubMed ID: 23010706
    [TBL] [Abstract][Full Text] [Related]  

  • 54. HPV testing is an efficient management choice for women with inadequate liquid-based cytology in cervical cancer screening.
    Giorgi Rossi P; Carozzi F; Collina G; Confortini M; Dalla Palma P; De Lillo M; Del Mistro A; Ghiringhello B; Gillio-Tos A; Maioli P; Pellegrini A; Schiboni ML; Segnan N; Zaffina LM; Zorzi M; Ronco G;
    Am J Clin Pathol; 2012 Jul; 138(1):65-71. PubMed ID: 22706859
    [TBL] [Abstract][Full Text] [Related]  

  • 55. 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities.
    Wright TC; Cox JT; Massad LS; Twiggs LB; Wilkinson EJ;
    JAMA; 2002 Apr; 287(16):2120-9. PubMed ID: 11966387
    [TBL] [Abstract][Full Text] [Related]  

  • 56. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer.
    Wright TC; Denny L; Kuhn L; Pollack A; Lorincz A
    JAMA; 2000 Jan; 283(1):81-6. PubMed ID: 10632284
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Does typing of human papillomavirus assist in the triage of women with repeated low-grade, cervical cytologic abnormalities?
    Fait G; Daniel Y; Kupferminc MJ; Lessing JB; Niv J; Bar-Am A
    Gynecol Oncol; 1998 Sep; 70(3):319-22. PubMed ID: 9790781
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Expression of p16/Ki-67 in ASC-US/LSIL or Normal Cytology with Presence of Oncogenic HPV DNA.
    Solares C; Velasco J; Álvarez-Ruiz E; González-Fernández L; Encinas AI; Astudillo A; Schneider J
    Anticancer Res; 2015 Nov; 35(11):6291-5. PubMed ID: 26504065
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Follow-up testing after colposcopy: five-year risk of CIN 2+ after a colposcopic diagnosis of CIN 1 or less.
    Katki HA; Gage JC; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Kinney WK
    J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S69-77. PubMed ID: 23519308
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Primary screening for high risk HPV by home obtained cervicovaginal lavage is an alternative screening tool for unscreened women.
    Nobbenhuis MA; Helmerhorst TJ; van den Brule AJ; Rozendaal L; Jaspars LH; Voorhorst FJ; Verheijen RH; Meijer CJ
    J Clin Pathol; 2002 Jun; 55(6):435-9. PubMed ID: 12037026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.